e8vk
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   May 13, 2003

United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)
         
Delaware   000-26301   52-1984749
 
 
(State or Other
Jurisdiction of
Incorporation)		   (Commission
File Number) 		  (I.R.S. Employer
Identification Number)
         
1110 Spring Street
Silver Spring, MD		    
20910		  
   
 
(Address of Principal Executive Offices)     (Zip Code)  

Registrant’s telephone number, including area code:

(301) 608-9292

 

 

Item 5. Other Events.

     On May 13, 2003, United Therapeutics Corporation (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1, announcing that Roger Jeffs, Ph.D., its President and Chief Operating Officer, has adopted a prearranged trading plan in accordance with Securities and Exchange Commission Rule10b5-1.

Item 7. Exhibits

          (c) Exhibits
       
  Exhibit No.   Description of Exhibit
 
  99.1   Press release dated May 13, 2003

 

 

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    UNITED THERAPEUTICS CORPORATION  
 
Dated: May 13, 2003   By:  /s/ Paul A. Mahon  
     
Name: Paul A. Mahon
Title: SVP and General Counsel		  

 

 

EXHIBIT INDEX

     
Exhibit No.   Description of Exhibit
 
99.1   Press release dated May 13, 2003